AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 32 min read$AMGN

Amgen: Q3 Earnings Snapshot

Amgen Inc. (AMGN) reported Q3 net income of $3.86B, or $7.08 per share, exceeding analyst expectations. Revenue was $10.37B, also topping forecasts. The company raised its full-year earnings and revenue guidance. AMGN shares are up 41% YTD and 56% over the past year.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 9:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Amgen: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AMGNBullishHigh
01

Why it matters

The earnings beat and raised guidance are likely to push the stock higher in the next trading session.

02

Market read

First report of Amgen's Q3 earnings, a material event for a large‑cap biotech, with clear upside potential.

03

What to watch

Potential pipeline setbacks or regulatory risks not covered in the earnings release.

Relevance 9/10Novelty 9/10Timing: after‑hours

Background

Amgen's Q3 results were released via an automated press release citing Zacks data.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen reported Q3 net income of $3.86 B and EPS of $7.08, beating Zacks estimates of $5.74 per share.

Expected impact

upward pressure as the market prices in the earnings beat and upbeat guidance

Evidence & confidence

Large‑cap biotech with a 41% YTD gain; beat on both earnings and revenue and raised full‑year outlook, which typically drives short‑term buying.

Market effects

Sector

Biotech sector may see a rally as Amgen's beat reinforces demand for pharma earnings.

Regional

U.S. markets could open higher on biotech optimism.

Global

Amgen's guidance may influence global biotech sentiment and related ADRs.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face short‑term profit‑taking.

Key entities

  • Company
    Amgen Inc.

    World's largest biotech drugmaker.

Read at source← All news

StoryAmgen posts Q3 2026 earnings beat and lifts full‑year revenue and profit guidance

Also covered by

6 outlets

Related articles

NOV 3
$AMGNMedAI 8/10

Why is Amgen stock sliding today?

Amgen (AMGN) stock fell 1.6% in after-hours trading despite beating earnings estimates. Revenue rose 8% to $10.4B, but Prolia and XGEVA sales dropped 45% and 47% respectively due to biosimilar competition. Guidance was in line with expectations, and R&D expenses increased 11%. The broader market was mixed, with midterm elections adding macro uncertainty.

investing.com2 min
NOV 3
$AMGNHighAI 9/10

Amgen third quarter sales rise 8%, led by cholesterol, cancer drugs

Amgen reported an 8% rise in third-quarter sales, driven by Repatha, Imdelltra, and Uplizna. Adjusted earnings per share increased 14% to $6.45, surpassing estimates. Revenue reached $10.4 billion, exceeding expectations. Amgen raised its full-year outlook, projecting adjusted earnings of $22.90 to $23.70 per share on revenue of $38.9 billion to $39.7 billion. Key drugs like Repatha and Evenity saw significant sales growth, while Prolia declined due to competition.

finance.yahoo.com2 min